eukaryotic translation initiation factor 3 subunit K pseudogene 1Genealiases: []
Q-omics provides the consensus-scored EIF3KP1 profile across patient tissues and cancer cell-line models. EIF3KP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, EIF3KP1 is differentially expressed in 6, with the highest sampling consensus in LUAD. Additionally, EIF3KP1 RNA expression shows 9,462 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, LUAD, and KIRP as cancer lineages where EIF3KP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF3KP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF3KP1 survival associations across molecular data types. EIF3KP1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF3KP1 RNA expression–survival associations across cancer types. High EIF3KP1 expression shows unfavorable associations in UVM, MESO, KIRC, OV and STAD, but favorable associations in SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for EIF3KP1 RNA expression.
This table summarizes EIF3KP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF3KP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF3KP1 shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in KIRC, THCA and HNSC. The LUAD box plot shows higher EIF3KP1 RNA expression in normal versus tumor tissue (log2 FC = −0.504, t-test p < 0.001).
This table shows molecular features associated with EIF3KP1 in patient tissues and cancer cell lines. In patient samples, EIF3KP1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
